Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Altimmune (ALT) Asset Writedowns and Impairment (2016 - 2021)

Altimmune (ALT) has disclosed Asset Writedowns and Impairment for 4 consecutive years, with $3.3 million as the latest value for Q4 2021.

Quarterly Asset Writedowns and Impairment changed N/A to $3.3 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $11.4 million through Dec 2021, changed N/A year-over-year, with the annual reading at $12.4 million for FY2023, N/A changed from the prior year.
Asset Writedowns and Impairment for Q4 2021 was $3.3 million at Altimmune, up from $30000.0 in the prior quarter.
The five-year high for Asset Writedowns and Impairment was $24.5 million in Q4 2018, with the low at $30000.0 in Q3 2021.
Average Asset Writedowns and Impairment over 3 years is $6.2 million, with a median of $2.2 million recorded in 2019.